Background: Data on the effectiveness and safety of oral anticoagulant (OAC) agents in very elderly nonvalvular atrial fibrillation patients with high bleeding risk are lacking.
Objectives: This study examined 2-year outcomes and effects of OAC agents among these patients using the ANAFIE (All Nippon Atrial Fibrillation in the Elderly) registry (N = 32,275) data.
Methods: Patients were classified into high-risk (age: ≥80 years; CHADS score: ≥2; and presence of ≥1 bleeding risk factor: creatinine clearance of 15-30 mL/minute, prior bleeding at critical sites, body weight of ≤45 kg, or continuous antiplatelet use) and reference groups.
Results: In the high-risk (n = 7,104) and reference (n = 25,171) group patients, 89.0% and 93.4%, respectively, used OAC agents. Of these, respectively, 30.1% and 24.2% used warfarin, and 58.9% and 69.1% used direct-acting OAC (DOAC) agents. Compared with the reference group, the high-risk group had higher incidences of stroke/systemic embolism, major bleeding, intracranial hemorrhage, gastrointestinal bleeding, cardiovascular events, and all-cause death. In the high-risk group, DOAC agent use vs nonuse of OAC agents was associated with reduced incidences of stroke/systemic embolism (HR: 0.53; 95% CI: 0.36-0.79) and all-cause death (HR: 0.65; 95% CI: 0.52-0.81) but not with major bleeding (HR: 1.09; 95% CI: 0.63-1.89). DOAC agents were superior to warfarin in effectiveness and safety. For high-risk patients, history of major bleeding, severe liver dysfunction, and falls within 1 year were independent risk factors for major bleeding.
Conclusions: High-risk elderly nonvalvular atrial fibrillation patients had higher event incidences. DOAC agents were associated with reduced risk of stroke/systemic embolism and all-cause death vs nonuse of OAC agents or warfarin. (Prospective Observational Study in Late-Stage Elderly Patients With Nonvalvular Atrial Fibrillation [ANAFIE registry]; UMIN000024006).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700004 | PMC |
http://dx.doi.org/10.1016/j.jacasi.2022.07.008 | DOI Listing |
Clin Cardiol
January 2025
Second Department of Internal Medicine, University of Toyama, Toyama, Japan.
Ann Med
December 2025
Department of Clinical Pharmacology, Flinders Medical Centre, Southern Adelaide Local Health Network, Adelaide, Australia.
Background: Most older patients with atrial fibrillation (AF) have comorbidities. However, it is unclear whether specific comorbidity patterns are associated with adverse outcomes. We identified comorbidity patterns and their association with mortality in multimorbid older AF patients with different multidimensional frailty.
View Article and Find Full Text PDFJ Coll Physicians Surg Pak
January 2025
Department of Cardiovascular Medicine, Second People's Hospital of Anhui Province, Hefei, China.
Objective: To explore the prognostic significance of Sestrin-2 and Galectin-3 levels in atrial fibrillation complicated by left atrial remodelling, aiming to offer novel insights for prevention, treatment, and follow-up strategies.
Study Design: Analytical study. Place and Duration of the Study: Department of Cardiology, Second People's Hospital of Anhui Province, Hefei, China, from January 2021 to December 2023.
BMC Cardiovasc Disord
January 2025
Department of Cardiology, Xuzhou Central Hospital, No.199 Jiefang South Road, Quanshan District, Xuzhou, 221009, People's Republic of China.
Background: The aim of this study is to identify factors associated with the development of long-term severe tricuspid regurgitation (TR) following mitral valve replacement (MVR).
Methods: A retrospective analysis was conducted involving 308 patients who underwent single-valve MVR at Xuzhou Central Hospital between April 2017 and December 2022. Preoperative color Doppler ultrasound indicated that all patients had either no or mild to moderate tricuspid regurgitation.
BMC Anesthesiol
January 2025
Department of Anaesthesiology, West China Hospital, Sichuan University & The Research Units of West China (2018RU012), Chinese Academy of Medical Sciences, Chengdu, 610041, China.
Background: Given the prevalence of cardiovascular disease, encountering difficult airways in this patient population is quite common. The challenge for anesthesiologists lies not only in establishing the airway but also in managing the hemodynamic instability caused by sympathetic activation during intubation. The purpose of this report is to describe the anesthetic experience of this patient with severe mitral and tricuspid regurgitation, atrial fibrillation with rapid ventricular response, and moderate pulmonary hypertension with an anticipated difficult airway.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!